Diabytes
USFDA completes inspection of Cadila's Changodar plant
Drug firm Cadila Healthcare today said the USFDA has completed inspection of its manufacturing plant at Changodar with "no observation".
Trending Photos
12- 10
- 10
- 10
New Delhi: Drug firm Cadila Healthcare today said the USFDA has completed inspection of its manufacturing plant at Changodar with "no observation".
The United States Food and Drug Administration (USFDA) inspected the company's topical manufacturing facility at Changodar from April 3-7, 2017, Cadila Healthcare said in a BSE filing.
"At the end of the inspection, no observation (483) is issued," it added.
The company has filed 17 products with the FDA from this facility, Cadila Healthcare said.
Cadila Healthcare stock today closed 1.51 percent up at Rs 454.85 per scrip on BSE.
 "DNA: Will government take your property?")
 "DNA: Video of 'Maoist conspiracy' on Rahul Gandhi's seat")
 "DNA: Jailed Sheikh Shahjahan breaks down on camera")
 "DNA: Is your car insurance fake?")
 "DNA: How to stop Hindu-Muslim politics?")
 "DNA: What is saccharin and artificial sweetener?")
 "DNA: Will world drown in glacier water?")
 "DNA: PM Modi's attack on Congress over Hanuman Chalisa")
 "DNA: Hong Kong, Singapore food regulators find cancer-causing chemicals in Everest")
 "DNA: Analysis of BJP's first victory in Lok Sabha elections")
